secwatch.observer — SEC 8-K summary
======================================

Issuer:     Longevity Health Holdings, Inc. (XAGE)
CIK:        0001842939
Form:       8-K
Filed at:   2024-04-01T23:59:59+00:00
Accession:  0000950170-24-039431
Event type: m_and_a
Sentiment:  positive
Materiality: 0.80
Item codes: 2.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Carmell completes sale of Axolotl Biologix, expects $4M annual cash burn reduction
--------------------------------------------------------------------------------

- Sale closed March 26; consideration: 3.845M common shares, 4,243 preferred shares, cancellation of $8M notes payable.
- Annualized cash burn expected to drop $4M based on AxoBio's January 2024 financials.
- Total debt reduction of $15.6M ($7.6M subsidiary debt + $8M notes payable).
- Tangible equity increased $7M from eliminating AxoBio's negative tangible equity.
- EPS dilution reduced 29% via cancellation of 8.09M fully diluted shares; 19.25M shares outstanding post-closing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1842939/000095017024039431/0000950170-24-039431-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1842939/000095017024039431/ctcx-20240326.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-039431

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer